A mogat2 inhibitor compound and uses thereof
By developing fused heterocyclic aromatic compounds to inhibit MOGAT2 enzyme activity, MOGAT2 inhibitor drugs were prepared, solving the problem of insignificant efficacy of existing compounds and achieving effective treatment for obesity and metabolic syndrome.
CN122381071APending Publication Date: 2026-07-14EVOPOINT BIOSCIENCES CO LTD
Patent Information
- Application Number
- CN202512001501.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2025-03-27
- Filing Date
- 2025-12-29
- Publication Date
- 2026-07-14
AI Technical Summary
Technical Problem
Existing MOGAT2 inhibitor compounds have not shown significant efficacy in clinical trials and are not effective in treating metabolic diseases such as obesity and non-alcoholic fatty liver disease.
Method used
A fused heterocyclic aromatic compound and its pharmaceutically acceptable salt are provided, which are prepared as MOGAT2 inhibitor drugs by inhibiting MOGAT2 enzyme activity for the treatment of diseases such as obesity and metabolic syndrome.
Benefits of technology
This compound exhibits significant MOGAT2 inhibitory activity and has the potential to treat obesity and improve metabolic syndrome. Its IC50 value effectively inhibits enzyme activity within a certain range.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN122381071A_ABST
Abstract
The present application provides a compound shown in formula I, wherein R1, R2, R3 are defined in the specification. The compound shown in formula I of the present application can effectively inhibit MOGAT2 enzyme activity, and has a clinical application prospect for treating and / or preventing obesity, metabolic syndrome, hyperlipidemia, hypertriglyceridemia, high VLDL, high fatty acid, diabetes or arteriosclerosis.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Working vehicle for inspecting and repairing bridge
JP1988040005A
Pharmaceutical composition containing fused ring derivative with MGAT2 inhibitory activity
JP2020111571A
Fused ring derivatives with MGAT2 inhibitory activity
JP2023055851A
Aryl dihydropyridinone and piperidinone as MGAT2 inhibitors
WO2013082345A1
Fused ring derivative having mgat-2 inhibitory activity
WO2019013311A1